The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.
Aged 18 years or older
Liver
Adrenal
Abdomino-pelvic lymph node
Contra-indication to MRI
Previous high dose radiotherapy to a site requiring stereotactic treatment (including SIRTEX). Further SABR treatment of lesions previously treated with SABR or high dose radiotherapy is not permitted in this trial.
Substantial overlap with a previously treated high dose (definitive or stereotactic dose) radiation volume.
Primary prostate cancer, carcinoid tumours, germ cell tumours, lymphoma, small cell tumours
Australasian Gastro-Intestinal Trials Group
Lead sponsor
Trans Tasman Radiation Oncology Group
Collaborator